Cargando…

The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells

Neuroblastoma (NBL) originates from undifferentiated cells of the sympathetic nervous system. Chemotherapy is judged to be suitable for successful treatment of this disease. Here, the influence of histone deacetylase (HDAC) inhibitor valproate (VPA) combined with DNA-damaging chemotherapeutic, ellip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cerna, Tereza, Hrabeta, Jan, Eckschlager, Tomas, Frei, Eva, Schmeiser, Heinz H., Arlt, Volker M., Stiborová, Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796113/ https://www.ncbi.nlm.nih.gov/pubmed/29304031 http://dx.doi.org/10.3390/ijms19010164

Ejemplares similares

The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells
por: Poljaková, Jitka, et al.
Publicado: (2008)

DNA and histone deacetylases as targets for neuroblastoma treatment
por: Stiborová, Marie, et al.
Publicado: (2010)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine
por: Stiborová, Marie, et al.
Publicado: (2017)

Ellipticine cytotoxicity to cancer cell lines — a comparative study
por: Stiborová, Marie, et al.
Publicado: (2011)

Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells
por: Hřebačková, Jana, et al.
Publicado: (2009)

The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes
por: Stiborová, Marie, et al.
Publicado: (2014)

Induced expression of microsomal cytochrome b(5) determined at mRNA and protein levels in rats exposed to ellipticine, benzo[a]pyrene, and 1-phenylazo-2-naphthol (Sudan I)
por: Stiborová, Marie, et al.
Publicado: (2016)

Valproic Acid Increases CD133 Positive Cells that Show Low Sensitivity to Cytostatics in Neuroblastoma
por: Khalil, Mohamed Ashraf, et al.
Publicado: (2016)

Application of hepatic cytochrome b(5)/P450 reductase null (HBRN) mice to study the role of cytochrome b(5) in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine
por: Reed, Lindsay, et al.
Publicado: (2019)

Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2
por: Aimová, Dagmar, et al.
Publicado: (2008)

Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells
por: Stockhausen, M-T, et al.
Publicado: (2005)

Valproic acid overcomes hypoxia-induced resistance to apoptosis
por: CIPRO, ŠIMON, et al.
Publicado: (2011)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Formation of DNA Adducts by Ellipticine and Its Micellar Form in Rats — A Comparative Study
por: Stiborova, Marie, et al.
Publicado: (2014)

Mechanisms of Enzyme-Catalyzed Reduction of Two Carcinogenic Nitro-Aromatics, 3-Nitrobenzanthrone and Aristolochic Acid I: Experimental and Theoretical Approaches
por: Stiborová, Marie, et al.
Publicado: (2014)

Balkan endemic nephropathy: an update on its aetiology
por: Stiborová, Marie, et al.
Publicado: (2016)

DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer
por: Stiborová, Marie, et al.
Publicado: (2017)

Heterologous expression of human cytochrome P450 2S1 in Escherichia coli and investigation of its role in metabolism of benzo[a]pyrene and ellipticine
por: Mrízová, Iveta, et al.
Publicado: (2016)

MIAT Is an Upstream Regulator of NMYC and the Disruption of the MIAT/NMYC Axis Induces Cell Death in NMYC Amplified Neuroblastoma Cell Lines
por: Feriancikova, Barbara, et al.
Publicado: (2021)

Active Site Mutations as a Suitable Tool Contributing to Explain a Mechanism of Aristolochic Acid I Nitroreduction by Cytochromes P450 1A1, 1A2 and 1B1
por: Milichovský, Jan, et al.
Publicado: (2016)

Comparison of the oxidation of carcinogenic aristolochic acid I and II by microsomal cytochromes P450 in vitro: experimental and theoretical approaches
por: Martínek, Václav, et al.
Publicado: (2017)

Fluorescence Characterization of Gold Modified Liposomes with Antisense N-myc DNA Bound to the Magnetisable Particles with Encapsulated Anticancer Drugs (Doxorubicin, Ellipticine and Etoposide)
por: Skalickova, Sylvie, et al.
Publicado: (2016)

Synergistic Effect of Simultaneous versus Sequential Combined Treatment of Histone Deacetylase Inhibitor Valproic Acid with Etoposide on Melanoma Cells
por: Shyu, Yueh-Ming, et al.
Publicado: (2021)

Rat cytochromes P450 oxidize 3-aminobenzanthrone, a human metabolite of the carcinogenic environmental pollutant 3-nitrobenzanthrone
por: Mizerovská, Jana, et al.
Publicado: (2008)

The impact of individual cytochrome P450 enzymes on oxidative metabolism of benzo[a]pyrene in human livers
por: Šulc, Miroslav, et al.
Publicado: (2016)

NADPH- and NADH-dependent metabolism of and DNA adduct formation by benzo[a]pyrene catalyzed with rat hepatic microsomes and cytochrome P450 1A1
por: Stiborová, Marie, et al.
Publicado: (2016)

Effects of the Histone Deacetylase Inhibitor Valproic Acid on Human Pericytes In Vitro
por: Karén, Jakob, et al.
Publicado: (2011)

Effects of histone deacetylase inhibitor valproic acid on skeletal myocyte development
por: Li, Qiao, et al.
Publicado: (2014)

NADH:Cytochrome b(5) Reductase and Cytochrome b(5) Can Act as Sole Electron Donors to Human Cytochrome P450 1A1-Mediated Oxidation and DNA Adduct Formation by Benzo[a]pyrene
por: Stiborová, Marie, et al.
Publicado: (2016)

Correction to NADH:Cytochrome b(5) Reductase and Cytochrome b(5) Can Act as Sole Electron Donors to Human Cytochrome P450 1A1-Mediated Oxidation and DNA Adduct Formation by Benzo[a]pyrene
por: Stiborová, Marie, et al.
Publicado: (2016)

Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples
por: Berendsen, Sharon, et al.
Publicado: (2019)

Comparison of human cytochrome P450 1A1-catalysed oxidation of benzo[a]pyrene in prokaryotic and eukaryotic expression systems
por: Stiborová, Marie, et al.
Publicado: (2017)

Contribution of biotransformation enzymes to the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions, difficult answers
por: Stiborová, Marie, et al.
Publicado: (2008)

Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo
por: Dračínská, Helena, et al.
Publicado: (2016)

HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice
por: Scholz, Beatrix, et al.
Publicado: (2019)

A Mechanism of O-Demethylation of Aristolochic Acid I by Cytochromes P450 and Their Contributions to This Reaction in Human and Rat Livers: Experimental and Theoretical Approaches
por: Stiborová, Marie, et al.
Publicado: (2015)

Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro
por: ZHOU, YONG, et al.
Publicado: (2014)

Cross-Species Functional Genomic Analysis Identifies Resistance Genes of the Histone Deacetylase Inhibitor Valproic Acid
por: Forthun, Rakel Brendsdal, et al.
Publicado: (2012)

Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kgpds1po298egc82ffhcr1bcdc